Psilocybin for treating substance use disorders?
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Evidence based treatment for Substance use disorders (SUD) includes psychotherapy and pharmacotherapy. However, these are only partially effective. Hallucinogens, such as psilocybin, may represent potential new treatment options for SUD. This review provides a summary of (human) studies on the putative therapeutic effects of psilocybin, and discusses the receptor systems, brain regions and cognitive and emotional processes mediating psilocybin's effects. Psilocybin's chemical structure is similar to that of serotonin. Dysregulations in the serotonin system are associated with alterations in stress hormones, such as cortisol, and mood disorders. After psilocybin administration cortisol levels spike and activate the executive control network, with subsequent increased control over emotional processes, and relief of negative thinking and persistent negative emotions. Preliminary data of ongoing alcohol and smoking addiction studies in humans shows promising effects of psilocybin administration on substance use. Importantly, psilocybin has a low risk of toxicity and dependence and can be used safely under controlled clinical conditions. Areas covered: This paper is a narrative review based on the search terms: psilocybin, substance use disorder, addiction, depression, serotonin. Literature on potential efficacy and mechanisms of action of psilocybin in SUD is discussed. Expert commentary: Recent positive findings with psilocybin need confirmation in well-designed placebo controlled randomized trials employing a large sample size.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Large-scale brain networks and psychopathology: a unifying triple network model
Menon, V. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.08.003 · Cited by 4,168 · cited 3×
“This triple network model proposed by Menon [86] and involving the SN, DMN, and ECN was adapted by Sutherland et al. [87] who suggested that the SN is important for dynamic switching between the DMN and ECN.”
BackgroundMethodDavidson, M. C., Amso, D., Anderson, L. C., & Diamond, A. (2006) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2006.02.006 · Cited by 2,226
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“Current findings suggest that psilocybin may support drug-dependent individuals in overcoming their SUD [37].”
Limbic Activation During Cue-Induced Cocaine Craving
Childress, A. R., Mozley, P. D., McElgin, W., Fitzgerald, J., Reivich, M., & O’Brien, C. P. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.11 · Cited by 1,513 · cited 1×
“with cue-induced drug craving and anxiety [77].”
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 3×
“scene, as in various studies for the treatment of anxiety and obsessive compulsive disorder [32,39].”
BackgroundHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 1×
“This can consequently lead to increased or decreased neuronal activity depending on the specific brain area [51].”
BackgroundStetler, C., & Miller, G. E. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31820ad12b · Cited by 1,123 · cited 3×
“Early life adversity and aberrant function of the HPA-axis have also been associated with MDD [79] and SUD [80], although the precise mechanisms are not fully clear yet.”
BackgroundPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 2×
“[54] reported that pretreatment with ketanserin, a selec-”
BackgroundPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 1×
“[34]) Tobacco dependence n = 15 Weeks 2–15, 6-month follow-up 80% abstinence at 6-month follow-up Session 1: 5 weeks after PST 0.”
BackgroundMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 1×
“scene, as in various studies for the treatment of anxiety and obsessive compulsive disorder [32,39].”
BackgroundThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 2×
“below) and pharmacological properties, human experimental research on the neuropsychological effects of psilocybin has revived since the late 1990s (for review [40,41]).”
BackgroundAssociative processes in addiction and reward. The role of amygdala-ventral striatal subsystems
EVERITT, B. J., PARKINSON, J. A., OLMSTEAD, M. C., ARROYO, M., ROBLEDO, P., & ROBBINS, T. W. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb09280.x · Cited by 708 · cited 1×
“reinforcement, psychomotor activation, Pavlovian conditioning, and cue-induced drug seeking behavior [63].”
BackgroundSerotoninergic regulation of emotional and behavioural control processes
Cools, R., Roberts, A. C., & Robbins, T. W. (2008) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2007.10.011 · Cited by 656
The comorbidity of depression and substance use disorders
Swendsen, J. (2000) · Clinical Psychology Review · doi:10.1016/s0272-7358(99)00026-4 · Cited by 632
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583 · cited 1×
“Several studies suggested an anti-SUD potential, by showing improvements in self-acceptance and interpersonal relationships, and reductions in craving and alcohol use in the treatment of alcohol dependence [21,22].”
BackgroundThe pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
The dark side of emotion: the addiction perspective
Koob, G. F. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.044 · Cited by 433 · cited 3×
“Next to the monoamine neurotransmitter systems, neuropeptides (like CRF) are also significantly involved in SUD, as reviewed by Koob [12].”
BackgroundInfluentialBrain stress systems in the amygdala and addiction
Koob, G. F. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.038 · Cited by 388 · cited 1×
“dala, where CRF is abundantly expressed [14].”
Prediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369
The modulatory effects of corticosteroids on cognition: studies in young human populations
Lupien, S. J., Wilkinson, C. W., Brière, S., Ménard, C., Ng Ying Kin, N. M. K., & Nair, N. P. V. (2002) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(01)00061-0 · Cited by 353 · cited 1×
“[83] showed cortisol is necessary for learning and memory in humans.”
BackgroundLYSERGIC ACID DIETHYLAMIDE: SIDE EFFECTS AND COMPLICATIONS
COHEN, S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196001000-00005 · Cited by 287
Psilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276
Human psychopharmacology of N,N-dimethyltryptamine
Strassman, R. J. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00081-2 · Cited by 261
Boulougouris, V., Glennon, J. C., & Robbins, T. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301584 · Cited by 219 · cited 1×
“It has been demonstrated that 5-HT2A receptor antagonism impairs behavioral flexibility by increasing perseveration [93], suggesting that 5-HT2A agonism has a beneficial effect on behavioral flexibility.”
BackgroundRapid relapse generally follows treatment for substance use disorders among adolescents
Cornelius, J. R., Maisto, S. A., Pollock, N. K., Martin, C. S., Salloum, I. M., Lynch, K. G., & Clark, D. B. (2003) · Addictive Behaviors · doi:10.1016/s0306-4603(01)00247-7 · Cited by 153
Kraehenmann, R., Schmidt, A., Friston, K., Preller, K. H., Seifritz, E., & Vollenweider, F. X. (2016) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.08.009 · Cited by 104 · cited 1×
“[88] found that psilocybin reduced stressor-induced modulation of amygdala connectivity (part of the SN) which may explain the potential of psilocybin to shift emotional biases”
BackgroundFurr, A., Lapiz-Bluhm, M. D., & Morilak, D. A. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001441 · Cited by 74 · cited 1×
“Indeed, 5-HT2A receptors in the orbitofrontal cortex facilitate reversal learning [94].”
BackgroundLaussmann, T., & Meier-Giebing, S. (2010) · Forensic Science International · doi:10.1016/j.forsciint.2009.12.013 · Cited by 56 · cited 3×
“Psilocybin is the main psychedelic ingredient of mushrooms of the genus Psilocybe [38] that has been used both in the lay scene, as in various studies for the treatment of anxiety and obsessive compulsive disorder [32,39].”
BackgroundInfluentialHata, T., Chen, J., Ebihara, K., Date, Y., Ishida, Y., & Nakahara, D. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07808.x · Cited by 25
Cited by
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance
Dinis-Oliveira, R. J. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1278228 · Cited by 224
Nicosia, N., Giovenzana, M., Misztak, P., Mingardi, J., & Musazzi, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126521 · Cited by 135
Heuschkel, K., & Kuypers, K. P. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00224 · Cited by 86
Psychedelic therapy: a roadmap for wider acceptance and utilization
Marks, M., & Cohen, I. G. (2021) · Nature Medicine · doi:10.1038/s41591-021-01530-3 · Cited by 59
Metadata
- Authors
- de Veen, B. T. H., Schellekens, A. F. A., Verheij, M. M. M., & Homberg, J. R.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2016-08-12
- Volume
- 17
- Issue
- 2
- Pages
- 203-212
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2499216663
- Cited by
- 99
- References
- 33
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.